From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.16
First Reported 1997
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 1.04
Pain Relevance 0.79

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Adh7) nucleolus (Adh7) intracellular (Adh7)
cytoplasm (Adh7)
Anatomy Link Frequency
external 1
Adh7 (Mus musculus)
Pain Link Frequency Relevance Heat
alcohol 18 100.00 Very High Very High Very High
agonist 5 94.24 High High
antagonist 1 83.68 Quite High
Antihistamine 1 60.64 Quite High
tricyclic antidepressant 1 56.24 Quite High
cINOD 1 31.60 Quite Low
cva 3 25.00 Low Low
Pain 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Prostate Cancer 56 99.74 Very High Very High Very High
Cancer 26 97.10 Very High Very High Very High
Toxicity 5 83.68 Quite High
Disease 20 50.00 Quite Low
Hypoglycemia 1 36.88 Quite Low
INFLAMMATION 1 30.16 Quite Low
Osteoporosis 13 5.00 Very Low Very Low Very Low
Hot Flashes 8 5.00 Very Low Very Low Very Low
Metabolic Syndrome 7 5.00 Very Low Very Low Very Low
Diabetes Mellitus 7 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Drugs may affect the pharmacokinetics of alcohol by altering gastric emptying and inhibiting gastric alcohol dehydrogenase.
Negative_regulation (inhibiting) of gastric alcohol dehydrogenase associated with alcohol
1) Confidence 0.16 Published 1997 Journal Clin Pharmacokinet Section Abstract Doc Link 9260032 Disease Relevance 0 Pain Relevance 0.74
PC is the second and the third leading cause of cancer deaths in males in the United States and European Union countries, respectively.1 The most common form of treatment for advanced PC is androgen-deprivation therapy (ADT), which can take the form of either surgical castration (orchiectomy) or medical castration (with luteinizing hormone-releasing hormone [LHRH] agonist).2 In addition, more and more patients with unfavorable intermediate- and high-risk adenocarcinoma of the prostate are treated with combination of ADT and primary external beam radiation therapy (EBRT), which seems to be the most appropriate treatment.3–5 As shown in a Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) report, the use of neoadjuvant hormones with radiotherapy (RT) increased from 9.8% to 74.6% during 1989–1992 and 1999–2001, and from 15.3% to 89.5% during the same periods in high-risk patients.6 A report by Shahinian et al indicated that use of ADT increased steadily throughout the 1990s among men of all ages with PC who had all stages and grades of tumor.7 These numbers highlight the need for good understanding of such treatment approach.
Negative_regulation (deprivation) of ADT in external associated with cancer, agonist and prostate cancer
2) Confidence 0.01 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004567 Disease Relevance 1.04 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools